The Race To Develop A Brain Cancer Treatment Takes An Interesting Turn

Biotechnology stocks have produced some of the biggest gains during the past couple of years.  While many analysts don?t expect that trend to change anytime soon, investors should still do all they can do to identify areas that have the most potential for success over the coming years.  One area that represents a major unmet need is glioblastoma multiforme, known as GBM.  GBM is the most common and most aggressive malignant primary brain tumor in humans, involving glial cells and accounting f...